A Phase 1 interventional study of Infliximab in Rheumatoid Arthritis, sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-11.
Sponsored by Taizhou Mabtech Pharmaceutical Co.,Ltd · Phase 1, Interventional, and Other
A phase 1, Randomized, Double-blind, Parallel group, Sing-dose study to compare the Pharmacokinetics and Safety of CMAB008 and Remicade in healthy subjects.
3,554 studies on the registry are indexed under Arthritis; 318 are open to participants now.
This study's enrollment of 90 is close to the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Taizhou Mabtech Pharmaceutical Co.,Ltd is the lead sponsor of 18 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Infliximab
Drug: Infliximab
100mg/vial
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to 1680 Hours After the Single Infusion of CMAB008/Remicade
Time frame: up to 1680 hours
Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade
Time frame: up to 1680 hours
Time of Maximum Concentration of Infliximab After the Single Infusion of CMAB008/Remicade
Time frame: up to 1680 hours
Area Under the Plasma Concentration-time Curve From Zero (0) Hours Extrapolated to infinite time After the Single Infusion of CMAB008/Remicade
Time frame: up to 1680 hours
Total Frequency of AE/SAE Within the Whole Time of the Study
Time frame: up to 1680 hours
Percentage of Patients in Whom Bind or Neutralizing Antibodies to Infliximab Were Detected
Time frame: up to 1680 hours
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Taizhou Mabtech Pharmaceutical Co.,Ltd